ShiftLab's first device is nearing commercialization. Will it start a low-cost revolution?

Engineering professor Beth Kolko is on a mission to sell low-cost devices. She's dismayed at the current landscape, which favors high-cost devices because cheaper alternatives can't support the sales forces needed to sell them, according to one industry exec. Kolko said several projects she worked on in the lab were never commercialized, such as a low-cost ultrasound device. Kolko's Shift Labs aims to change that, and has three low-cost devices in the pipeline. One is the $350 DripAssist, which measures the rate of delivery of intravenous drugs. Kolko hopes to get it past the FDA and onto the market by the end of the year. More

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.